Presentation is loading. Please wait.

Presentation is loading. Please wait.

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program  Solange.

Published byViviane Beauchamp Modified over 5 years ago

Similar presentations

Presentation on theme: "Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program  Solange."— Presentation transcript:

1 Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program  Solange Peters, MD, PhD, Alessandra Curioni-Fontecedro, MD, Hovav Nechushtan, MD, PhD, Jin-Yuan Shih, MD, PhD, Wei-Yu Liao, MD, PhD, Oliver Gautschi, MD, Vito Spataro, MD, Mojca Unk, MD, James Chih-Hsin Yang, MD, PhD, Robert M. Lorence, MD, PhD, Philippe Carrière, MD, Agnieszka Cseh, MD, Gee-Chen Chang, MD  Journal of Thoracic Oncology  Volume 13, Issue 12, Pages (December 2018) DOI: /j.jtho Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 ERBB2 mutation types identified in patients participating in the NPU program. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Computed tomography scans at baseline (A) and after 6 weeks of afatinib treatment (B) in a Taiwanese patient with a p.A775_G776insYVMA insertion in exon 20 who achieved a PR. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Positron-emission tomography scans taken (A) before initiation of afatinib and (B) after ∼3 months of treatment in a European patient with a p.A775_G776insYVMA insertion in exon 20 who achieved a PR. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program  Solange."

Similar presentations

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H

Jos A. Stigt, MD, PhD, Richard Vossenkaul, MD, Wouter H
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer  Suzanne Jenkins, DPhil, James C-H.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer  Suzanne Jenkins, DPhil, James C-H.
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib  Suzanne Jenkins, DPhil, James Chih-Hsin.

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib  Suzanne Jenkins, DPhil, James Chih-Hsin.

Similar presentations

Ads by Google